Altogether, the 4 newest IgAN drugs -- sparsentan, targeted-release budesonide, iptacopan, and atrasentan -- were prescribed to less than 5% of patients in a 2024-2025 US database. A new study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results